Biocorp has entered into exclusive negotiations to connect its Mallya device with pharmaceutical company Sanofi’s diabetes care platform.
Part of Biocorp’s connected devices portfolio, Mallya is a smart sensor cap that can be clipped onto an insulin injection pen for automatic recording and the transmission of dosage information.
The device sends the captured information to a companion mobile application in real-time via Bluetooth technology.
The Mallya connected device can be reused for two years and provides track records of dose delivered, insulin type, and time and date for each injection.
The device, which can be used with existing platforms and digital solutions, comes with audio and visual signals intended to guide patients during the injection process.
Last month, Biocorp secured the European CE-Mark for Mallya as a class IIb medical device.
As per the terms of the exclusive negotiations with Sanofi, French firm Biocorp will initially receive a payment of €4m to support related development activities.
Biocorp chief operating officer Eric Dessertenne said: “We are proud to bring a breakthrough device to the market to improve the daily lives of patients with diabetes.
“We believe our innovative Mallya has great potential to become the standard in its class and should contribute significantly, and in a short time, to our very strong growth.”
The company, founded in 2004, develops medical devices and also smart drug delivery systems. Biocorp’s connected devices portfolio also includes Inspair, Onejet and Datapen.
Inspair is a smart cap designed to automatically capture each actuation of an inhaler and analyse the device’s usage.
Onejet is a Bluetooth-enabled motor driven auto-injector for the delivery of high viscosity products, while Datapen is a smart pen injector meant to facilitate easy treatment delivery.